The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Treatment of Hepatitis C Infection in Injection Drug Users
Open accessAbstract
Chronic hepatitis C is the most common infectious disease among injection drug users (IDUs). Because of the allegedly poor compliance of IDUs with treatment requirements and conditions, hepatologists recommend treatment only if former IDUs have spent 6 to 12 months drug free. The aim of this prospective study was to investigate whether opiate–dependent IDUs with chronic hepatitis C virus (HCV) infection can be treated successfully with interferon. Eligibility for the study meant IDUs had to be HCV–RNA positive by polymerase chain reaction. Subsequently 50 inpatients were enrolled during detoxification treatment. HCV treatment was started with interferon alfa–2a (through 1998) or a combined regimen consisting of interferon alfa–2a and ribavirin (begun in 1998). All patients were treated and supervised by specialized physicians in both hepatology and addiction medicine. The end point for this study was defined as a loss of detectable serum HCV RNA at week 24 after treatment. The rate of sustained virologic response was 36%. Sustained response rates were not significantly different for patients who relapsed and returned to treatment (53%), relapsed and did not return to treatment (24%), or did not relapse (40%; P > .05). During the 24 weeks after treatment, we were unable to detect any reinfection, even among patients who injected heroin during this period. This surprising result should be examined in further studies. In conclusion, HCV–infected drug addicts with chronic HCV infection can be treated successfully with interferon alfa–2a and ribavirin if they are closely supervised by physicians specialized in both hepatology and addiction medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M.-H., Cort, S., & Albrecht, J. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392101 · Cited by 3,465
The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994
Alter, M. J., Kruszon-Moran, D., Nainan, O. V., McQuillan, G. M., Gao, F., Moyer, L. A., Kaslow, R. A., & Margolis, H. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908193410802 · Cited by 2,992
Poynard, T., Marcellin, P., Lee, S. S., Niederau, C., Minuk, G. S., Ideo, G., Bain, V., Heathcote, J., Zeuzem, S., Trepo, C., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)07124-4 · Cited by 2,318
The Natural History of Community-Acquired Hepatitis C in the United States
Alter, M. J., Margolis, H. S., Krawczynski, K., Judson, F. N., Mares, A., Alexander, W. J., Hu, P. Y., Miller, J. K., Gerber, M. A., Sampliner, R. E., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212313272702 · Cited by 1,592
Alter, M. J. (1997) · Hepatology · doi:10.1002/hep.510260711 · Cited by 1,075
The Treatment of Chronic Viral Hepatitis
Hoofnagle, J. H., & Di Bisceglie, A. M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701303360507 · Cited by 946
EASL International Consensus Conference on Hepatitis C Paris, 26–28 February 1999
(1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80154-8 · Cited by 700
Poynard, T., Leroy, V, Cohard, M., Thevenot, T., Mathurin, P., Opolon, P., & Zarski, J. P. (1996) · Hepatology · doi:10.1002/hep.510240405 · Cited by 671
Alter, M. J. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450170079026 · Cited by 615
(1997) · Hepatology · doi:10.1002/hep.510260701 · Cited by 569
Cited by
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
Ghany, M. G., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2009) · Hepatology · doi:10.1002/hep.22759 · Cited by 2,973
Diagnosis, management, and treatment of hepatitis C†
Strader, D. B., Wright, T., Thomas, D. L., & Seeff, L. B. (2004) · Hepatology · doi:10.1002/hep.20119 · Cited by 1,709
American Gastroenterological Association Technical Review on the Management of Hepatitis C
Dienstag, J. L., & McHutchison, J. G. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.010 · Cited by 384
Limited Uptake of Hepatitis C Treatment Among Injection Drug Users
Mehta, S. H., Genberg, B. L., Astemborski, J., Kavasery, R., Kirk, G. D., Vlahov, D., Strathdee, S. A., & Thomas, D. L. (2008) · Journal of Community Health · doi:10.1007/s10900-007-9083-3 · Cited by 327
Schaefer, M., Schmidt, F., Folwaczny, C., Lorenz, R., Martin, G., Schindlbeck, N., Heldwein, W., Soyka, M., Grunze, H., Koenig, A., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50031 · Cited by 324
Kraus, M. L., Alford, D. P., Kotz, M. M., Levounis, P., Mandell, T. W., Meyer, M., Salsitz, E. A., Wetterau, N., & Wyatt, S. A. (2011) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e3182312983 · Cited by 266
Psychiatric and Substance Use Disorders in Individuals with Hepatitis C: Epidemiology and Management
Loftis, J. M., Matthews, A. M., & Hauser, P. (2006) · Drugs · doi:10.2165/00003495-200666020-00003 · Cited by 86
Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy
HALLINAN, R., BYRNE, A., AMIN, J., & DORE, G. J. (2005) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2005.03882.x · Cited by 56
Neri, S., Bertino, G., Petralia, A., Giancarlo, C., Rizzotto, A., Calvagno, G. S., Mauceri, B., Abate, G., Boemi, P., Di Pino, A., et al. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181d88af5 · Cited by 37
Woolhouse, S., Cooper, E., & Pickard, A. (2013) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2013.05.018 · Cited by 30
Metadata
- Authors
- Backmund, M., Meyer, K., Von Zielonka, M., & Eichenlaub, D.
- Venue
- Hepatology
- Published
- 2001-07
- Volume
- 34
- Issue
- 1
- Pages
- 188-193
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2037595198
- Cited by
- 256
- References
- 30
- FWCI
- 9.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.